Glucagon-like peptide 1 as a regulator of food intake and body weight: therapeutic perspectives.
about
GPR119, a novel G protein-coupled receptor target for the treatment of type 2 diabetes and obesityGLP-1, the gut-brain, and brain-periphery axesThe anorectic effect of GLP-1 in rats is nutrient dependentNeuroimaging, gut peptides and obesity: novel studies of the neurobiology of appetite.Resveratrol suppresses body mass gain in a seasonal non-human primate model of obesity.Encapsulation of 16-Hydroxycleroda-3,13-Dine-16,15-Olide in Mesoporous Silica Nanoparticles as a Natural Dipeptidyl Peptidase-4 Inhibitor Potentiated Hypoglycemia in Diabetic Mice.Decreased basal levels of glucagon-like peptide-1 after weight loss in obese subjects.Glucagon-like peptide-1 receptor agonists suppress water intake independent of effects on food intake.Peripheral regulation of food intake: new insights.Glucagon-like peptide 1 agonists and the development and growth of pancreatic beta-cells.Brain circuits regulating energy homeostasis.Pharmacologic modifications of hormones to improve their therapeutic potential for diabetes management.An emerging role of glucagon-like peptide-1 in preventing advanced-glycation-end-product-mediated damages in diabetesDesign, synthesis and crystallization of a novel glucagon analog as a therapeutic agent.Gut-brain neuropeptides in the regulation of ingestive behaviors and obesity.B-cell translocation gene 2 positively regulates GLP-1-stimulated insulin secretion via induction of PDX-1 in pancreatic β-cells.Long-term activation of PKA in β-cells provides sustained improvement to glucose control, insulin sensitivity and body weightDietary fiber in the prevention and treatment of metabolic syndrome: a review.Insulin granule biogenesis, trafficking and exocytosis.Sleeve gastrectomy: a new surgical approach for morbid obesity.Waking up the gut in critically ill patients.Glucagon-like peptide-1 analogues for Type 2 diabetes mellitus: current and emerging agents.Update on adipose tissue blood flow regulation.GPR119 agonists as potential new oral agents for the treatment of type 2 diabetes and obesity.Pancreatic gene variants potentially associated with dipeptidyl peptidase-4 inhibitor treatment response in Type 2 diabetes.Approved and Off-Label Uses of Obesity Medications, and Potential New Pharmacologic Treatment Options.Gut: A key player in the pathogenesis of type 2 diabetes?Central Control of Feeding Behavior by the Secretin, PACAP, and Glucagon Family of PeptidesEffects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with Type 2 diabetes.New therapeutic strategies for the treatment of type 2 diabetes mellitus based on incretins.The glucagon receptor is involved in mediating the body weight-lowering effects of oxyntomodulin.Physiological effects of dietary fructans extracted from Agave tequilana Gto. and Dasylirion spp.Potential modulation of plasma ghrelin and glucagon-like peptide-1 by anorexigenic cannabinoid compounds, SR141716A (rimonabant) and oleoylethanolamide.S 23521 decreases food intake and body weight gain in diet-induced obese rats.Intravenous infusion of glucagon-like peptide-1 potently inhibits food intake, sham feeding, and gastric emptying in rats.Sugar in coffee or tea and risk of obesity: A neglected issue.Agavins from Agave angustifolia and Agave potatorum affect food intake, body weight gain and satiety-related hormones (GLP-1 and ghrelin) in mice.Plasma nesfatin-1 levels are increased in patients with polycystic ovary syndrome.A 5-week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting glucagon-like peptide-1 analogue, in patients with type 2 diabetes.The alpha (α)-glucosidase inhibitor, acarbose, attenuates the blood pressure and splanchnic blood flow responses to intraduodenal sucrose in older adults.
P2860
Q24653673-38D7850F-01BA-40BF-A198-1265BD5F8E00Q27000749-AEF0EB8E-E68A-4CF5-855A-83B77AE7C379Q28484398-6433FE3B-7D05-47C5-8652-5D9A48E2CAB6Q33606106-82847F0B-B77F-4F00-82F1-19AC01851434Q33613030-074A1663-469D-4DD7-B14C-F5C7F193F8CBQ33742245-BF15B649-2CBF-4CDF-8CB9-9C1F61E478DEQ34632636-B1EB8765-6098-41DF-BCD3-02D0ACA2C1ABQ35601526-204C23E0-3F04-405C-9413-5469004ED051Q35724855-DFB3784E-44FC-400C-B365-60DFAE4481C5Q35772023-D136A88D-BABF-4048-A01E-14BCABE7703FQ35779160-09F50A30-4880-4A8F-9B81-9B9261D1F5ADQ36283816-25280843-85E4-4C6B-B62B-52276E650202Q36567296-C88B0729-CC1A-433F-98D6-0EE74598437CQ36585213-D300642F-9D5A-49BB-9278-08D813EF406CQ36616593-8E7BF8DC-0F99-47A3-A0A0-D4C5DE39621FQ36907211-316F45B3-0E65-498F-96FC-A876A49ED2C7Q37268207-E306F237-E128-4A0E-A19F-EF654C207971Q37307688-4B2612BC-BC0F-49FF-B90E-4D3D222E26FDQ37403987-A7702DC6-C681-4F9A-8258-142AAADE585BQ37688141-C50F086E-2C6B-409D-9C52-6DF32FE07B93Q37795946-CE2B797C-8DC9-4B33-AF9D-8548A69741D9Q37929159-7F81FDF9-0D06-4594-AB7B-EC4CCAC85FAAQ37982682-F8E34EBC-51B4-468D-9EB8-DB0899131573Q38089183-B2D41F79-A902-477A-9647-F59CE3331F2AQ38180221-652D19F4-BAC8-4919-B262-42BC2069444BQ38818675-346E83CF-9770-465A-884F-594226311489Q39021924-072FBC2D-7CED-45D6-B86B-D55FA5778F20Q39146023-722B50F3-2569-4595-A35F-AA5D70215D5DQ40404408-6AFE1458-7757-4FB6-AC12-2596E3834691Q42078124-CE357EB9-994E-450D-8778-19D0B5B949C3Q42255930-A761FB7B-AE20-4ECE-887E-204572E2AE94Q43351362-27D9812F-FA13-4F00-BA41-EA59BB969CCCQ45143864-AF16ABFC-938B-469E-8DDD-FD3117B286EDQ45145890-CDD69A63-872E-42CC-9D50-05F6700B6247Q45271809-2A0AED32-6E2E-4AEE-A28E-87B85DE9A99BQ46132702-E69E944C-2A0D-4EA9-83BE-65FCB8B90912Q47427418-388F6910-2B4B-4E7C-B26E-48FF2B70287AQ48720329-A6A07D69-7836-40BA-8F5F-6217A6038303Q51381372-1C5A802E-1D57-4A8E-BC29-72F5AC0FAFF1Q51456278-EA18C565-1B5A-47A9-82CA-1869B01C7144
P2860
Glucagon-like peptide 1 as a regulator of food intake and body weight: therapeutic perspectives.
description
2002 nî lūn-bûn
@nan
2002 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Glucagon-like peptide 1 as a r ...... ght: therapeutic perspectives.
@ast
Glucagon-like peptide 1 as a r ...... ght: therapeutic perspectives.
@en
Glucagon-like peptide 1 as a r ...... ght: therapeutic perspectives.
@nl
type
label
Glucagon-like peptide 1 as a r ...... ght: therapeutic perspectives.
@ast
Glucagon-like peptide 1 as a r ...... ght: therapeutic perspectives.
@en
Glucagon-like peptide 1 as a r ...... ght: therapeutic perspectives.
@nl
prefLabel
Glucagon-like peptide 1 as a r ...... ght: therapeutic perspectives.
@ast
Glucagon-like peptide 1 as a r ...... ght: therapeutic perspectives.
@en
Glucagon-like peptide 1 as a r ...... ght: therapeutic perspectives.
@nl
P2093
P1476
Glucagon-like peptide 1 as a r ...... ght: therapeutic perspectives.
@en
P2093
Juris J Meier
Michael A Nauck
Wolfgang E Schmidt
P304
P356
10.1016/S0014-2999(02)01434-6
P407
P577
2002-04-01T00:00:00Z